Efficacy trial of malaria vaccine SPf66 in Gambian infants.
about
Vaccines for preventing malaria (SPf66)A review of malaria vaccine clinical projects based on the WHO rainbow tableMerozoite surface proteins in red blood cell invasion, immunity and vaccines against malariaVaccines for malaria: how close are we?Multispecies Plasmodium infections of humansExtreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development.Defining clinical malaria: the specificity and incidence of endpoints from active and passive surveillance of children in rural Kenya.Integrated approach to malaria control.Current status of malaria and potential for control.Progress toward a malaria vaccine: efficient induction of protective anti-malaria immunity.Towards a blood-stage vaccine for malaria: are we following all the leads?Detecting Foci of Malaria Transmission with School Surveys: A Pilot Study in the Gambia.Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccineMalaria in the post-genomics era: light at the end of the tunnel or just another train?Vaccination against malaria with live parasites.Malaria vaccine trials: the missing qualitative data.Designing a malaria vaccine.Comparison of surveillance methods applied to a situation of low malaria prevalence at rural sites in The Gambia and Guinea Bissau.Murine infection models for vaccine development: the malaria example.Suppression of vaccine responses by malaria: insignificant or overlooked?Towards the development of a fully protective Plasmodium falciparum antimalarial vaccine.Recent advances in the development of a chemically synthesised anti-malarial vaccine.A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses.Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya.Serological responses of Gambian children to immunization with the malaria vaccine SPf66.Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine.Malaria vaccine: roadblocks and possible solutions.Research toward vaccines against malaria.Issues concerning malaria vaccine scientific, not based on racism.Vaccines, malaria, and a host of resistance.The protozoan view of the human condition.Estimates of the infectious reservoir of Plasmodium falciparum malaria in The Gambia and in Tanzania.Humoral immune responses during a malaria vaccine trial in Tanzanian infants.Immune responses to Plasmodium falciparum antigens during a malaria vaccine trial in Tanzanian children.A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants.Malaria in the 1990s: plus ça change, plus ça même chose.Randomization and baseline transmission in vaccine field trials
P2860
Q21032526-CF5A2F81-BE70-4624-8A84-6EC1FB83B770Q21034112-B32D7BAD-9120-446E-BB55-A50F3467F07CQ26772878-0626E430-11D7-45B7-9AEA-791CEE0BD2FCQ27024344-6A313411-A03C-4CBB-81C9-53A00EBC4648Q33596156-C6BE8215-56AB-4C1B-BE3A-1E8798447884Q33654911-C28464EC-2493-4BD4-8359-FCF5494618F8Q33778747-C0F62532-7AB2-4BAB-9420-266575860F28Q33906271-C26A896D-9657-4255-8FC0-9C553BA6EAF9Q33975652-69BB69A2-0B83-45EF-8DA6-A34FA46EBD76Q34280935-A4271C55-6C33-42E1-8CCA-E258DC7FC602Q34572160-F8ED0872-660C-45F6-A965-258067EAD443Q34796457-97634673-AAD1-4534-BBF4-51055951E421Q35005868-D3B725C6-8495-4D65-BFEE-CA606F7412C1Q35522550-DD217043-135C-4D0B-B83B-FF7C1E7E1326Q36600336-A5B3B55A-75E0-4065-AFC4-0457BD1A9492Q36827211-8B45F629-48A2-4FD3-BC80-271B56E64BA7Q37209392-7AC55302-9F94-4339-AE7B-18622D863E5BQ37470249-8253BF15-B0EE-4C6E-AFC6-9D378AB16B2EQ37478246-656773BB-5AC2-4105-813D-737B13A1CA5FQ37724859-BDB43C20-89EB-4C92-9266-C1A77775A2A3Q38059750-76FEEFEB-6A9B-4B9E-9E60-DB4F050A9FF3Q38560128-40BEFA4D-2D83-412C-A93C-6D3137949D21Q38952180-36A32C70-CF3B-4A1D-ACC7-5397BAB4A59BQ39130334-201A4991-99FC-472D-AE9B-955B0A316CA6Q39247939-2AB04CDD-9375-4975-AA86-05197353C126Q39372910-5C3305A0-75DF-48D7-A931-71042319DA0EQ40847091-6AD1B305-08D8-45A4-AAFB-07B4E998B777Q40859526-686DFA64-A798-491A-9299-F9D6BC162144Q42380117-2EA7D1F8-938E-437E-A0E9-61E06E0A1BB4Q43188767-087E0385-FF4B-47A0-B87C-FFE73E1E3E25Q43229169-4FB58208-D466-4826-8885-A30BD4EE5E3EQ43951299-CC7A191D-C291-497A-BA6F-BEC2D6E8587BQ43951508-C485EB70-50D6-49DC-A537-2E42338B9A91Q43952848-0BEE8E65-E1E5-4E7F-B936-F8F42FB1D1AEQ46821168-1589A487-1595-41B8-BF6D-B6D38B81D0C6Q48037225-464F5E87-049A-48C2-A975-B0AC44F71714Q57163790-A80CD2E4-5706-4233-886D-DFD91BEE5656
P2860
Efficacy trial of malaria vaccine SPf66 in Gambian infants.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Efficacy trial of malaria vaccine SPf66 in Gambian infants.
@en
type
label
Efficacy trial of malaria vaccine SPf66 in Gambian infants.
@en
prefLabel
Efficacy trial of malaria vaccine SPf66 in Gambian infants.
@en
P2093
P1433
P1476
Efficacy trial of malaria vaccine SPf66 in Gambian infants.
@en
P2093
B O Olaleye
C J Drakeley
G A Targett
M O George
P Langerock
U D'Alessandro
P304
P356
10.1016/S0140-6736(95)91321-1
P407
P50
P577
1995-08-01T00:00:00Z